Wall Street analysts expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to post sales of $286.10 million for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Integra LifeSciences Holdings Corporation’s earnings, with estimates ranging from $284.00 million to $288.80 million. Integra LifeSciences Holdings Corporation reported sales of $250.33 million in the same quarter last year, which suggests a positive year over year growth rate of 14.3%. The business is expected to issue its next quarterly earnings results on Thursday, October 26th.

According to Zacks, analysts expect that Integra LifeSciences Holdings Corporation will report full year sales of $286.10 million for the current financial year, with estimates ranging from $1.12 billion to $1.13 billion. For the next year, analysts forecast that the business will post sales of $1.26 billion per share, with estimates ranging from $1.19 billion to $1.55 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. During the same quarter in the previous year, the company posted $0.40 EPS. The business’s revenue for the quarter was up 13.2% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the company. BidaskClub downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. set a $60.00 price target on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald assumed coverage on Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They set an “overweight” rating and a $65.00 price target on the stock. Zacks Investment Research downgraded Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, June 28th. Finally, UBS AG reaffirmed a “buy” rating and issued a $60.00 target price (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a report on Friday, June 9th. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Integra LifeSciences Holdings Corporation presently has an average rating of “Buy” and a consensus target price of $52.63.

Integra LifeSciences Holdings Corporation (IART) opened at 49.81 on Thursday. The company has a market cap of $3.89 billion, a P/E ratio of 60.74 and a beta of 0.73. The firm has a 50-day moving average price of $52.89 and a 200 day moving average price of $46.88. Integra LifeSciences Holdings Corporation has a 12 month low of $40.51 and a 12 month high of $88.86.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/286-10-million-in-sales-expected-for-integra-lifesciences-holdings-corporation-iart-this-quarter/1468564.html.

In other news, Director Stuart Essig sold 140,000 shares of the stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $48.01, for a total value of $6,721,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. purchased 2,500 shares of the company’s stock in a transaction dated Thursday, August 3rd. The stock was purchased at an average price of $49.29 per share, with a total value of $123,225.00. Following the completion of the purchase, the director now directly owns 29,612 shares in the company, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. Insiders bought a total of 17,550 shares of company stock valued at $864,842 over the last quarter. 21.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in IART. Teachers Advisors LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 2.8% in the fourth quarter. Teachers Advisors LLC now owns 51,964 shares of the life sciences company’s stock worth $4,458,000 after buying an additional 1,392 shares during the last quarter. Foundry Partners LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 139.4% in the first quarter. Foundry Partners LLC now owns 52,960 shares of the life sciences company’s stock worth $2,231,000 after buying an additional 30,838 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Integra LifeSciences Holdings Corporation by 89.0% in the first quarter. Bank of Montreal Can now owns 8,642 shares of the life sciences company’s stock worth $364,000 after buying an additional 4,069 shares during the last quarter. First National Bank of Omaha boosted its position in shares of Integra LifeSciences Holdings Corporation by 154.6% in the first quarter. First National Bank of Omaha now owns 38,487 shares of the life sciences company’s stock worth $1,621,000 after buying an additional 23,371 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter worth approximately $1,180,000. Institutional investors own 86.77% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.